Prostate Cancer - Results from #760

Treatment patterns and outcomes in patients with nonmetastatic castration-resistant prostate cancer in the United States. July 31, 2024

Circulating Lipid Profiles Associated With Resistance to Androgen Deprivation Therapy in Localized Prostate Cancer. July 31, 2024

Real-world evaluation of access-driven Canadian treatment sequences in progressive prostate cancer (REACTIVATE). July 31, 2024

High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase 2 Trial. July 31, 2024

Briganti's 2012 nomogram is an independent predictor of prostate cancer progression in EAU intermediate-risk class: results from 527 patients treated with robotic surgery. July 31, 2024

Dual inhibition of ATR and DNA-PKcs radiosensitizes ATM-mutant prostate cancer. July 30, 2024

Organ-confined pT2 ISUP4/5 vs. nonorgan confined pT3/4 ISUP2 vs. ISUP3 prostate cancer: Differences in biochemical recurrence-free survival after radical prostatectomy. July 30, 2024

The Association between Patient Characteristics and Biochemical Recurrence after Radical Prostatectomy. July 30, 2024

Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies. July 30, 2024

Impact of Rectal Spacer on Toxicity Reduction in Men Treated With Proton Versus Photon Therapy. July 30, 2024

Performance of ChatGPT-4 and Bard chatbots in responding to common patient questions on prostate cancer 177Lu-PSMA-617 therapy. July 30, 2024

Design and Rationale of the Outcomes Database to Prospectively Assess the Changing Therapy Landscape in Renal Cell Carcinoma Registry: A Multi-institutional, Prospective Study of Patients with Metastatic Renal Cell Carcinoma. July 30, 2024

Cells in the Polyaneuploid Cancer Cell State are Pro-Metastatic. July 30, 2024

Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy. July 30, 2024

GATA2 promotes castration-resistant prostate cancer development by suppressing IFN-β axis-mediated antitumor immunity. July 30, 2024

Kataegis associated mutational processes linked to adverse prostate cancer presentation in African men. July 30, 2024

Correlates and predictors of sarcopenia among men with metastatic castrate-resistant prostate cancer. July 29, 2024

Do Prostate Imaging-Reporting and Data System (PIRADS) lesions predict holmium laser enucleation of prostate outcomes? July 29, 2024

Clinical Outcomes and Risk Stratification in Patients With Metastatic Hormone-Sensitive Prostate Cancer Treated With New-Generation Androgen Receptor Signaling Inhibitors. July 29, 2024

Readability and Information Quality in Cancer Information From a Free vs Paid Chatbot. July 29, 2024

Page 39 of 1449